Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Dan Feng
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07277322CT.gov Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases | — | Not Yet Recruiting | — | — | — |
NCT07106034CT.gov Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial | — | Not Yet Recruiting | — | — | — |
NCT06903858CT.gov Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06525428CT.gov Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05933980CT.gov Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT05963490CT.gov Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05167071CT.gov HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study | — | Active Not Recruiting | — | — | — |
NCT04653480CT.gov Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC | — | Unknown | — | — | — |
NCT04819516CT.gov Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04118933CT.gov A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer | — | Unknown | — | — | — |
Show 4 more trialsShow fewer
NCT03926338CT.gov Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer | — | Recruiting | — | — | — |
NCT03946917CT.gov JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT04110093CT.gov Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer | — | Unknown | — | — | — |
NCT03927898CT.gov Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Toripalimab (this asset) | Dan Feng | P2 | CCC · 54 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Toripalimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P3 | BB · 67 |
| Extranodal Nasal NK/T Cell Lymphoma | — | P3 | BB · 66 |
| Small Cell Lung Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Toripalimab in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/toripalimab-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →